

# HPV-Analysis

**- two perfect solutions for use in every lab -**

## HPV-screening Kit

(RDB2082)

Designed for initial HPV screening and screening before vaccination

Differentiation in 18 high- and 6 low risk HPV genotypes

Single detection of HPV 16 + 18

HPV-screening and HPV subtyping from one clinical sample

Conjugate c.  
Amplification c.  
HPV poly  
HPV high risk  
**HPV 16**  
**HPV 18**  
HPV low risk



## HPV-typing Kit

(RDB2080)

Subtyping of HPV high and low risk genotypes

Single detection of HPV 16, HPV 18, HPV 45 and the low risk types HPV 6 and 11

Group detection of thirties and fifties high risk types  
(HPV 31, 33, 35, 39, HPV 51, 52, 53, 56, 58, 59)

Allows the detection of multiple HPV infections and the observation of the development of infection

Conjugate control  
Amplification control  
HPV poly  
HPV high risk  
**HPV 16**  
**HPV 18**  
HPV 45  
HPV 30 HR group  
HPV 50 HR group  
HPV low risk  
**HPV 6**  
**HPV 11**



## Advantages of the AID HPV-program

Suitable for STD analysis in cervical scrapes, samples coated with paraffin wax and also usable for scrapes of oral and pharyngeal mucosa and blood.

Detection of single high risk HPV types allows evidence for a persistent HPV infection

Specific detection of the HPV types 6, 11, 16 and 18, suitable for a screening before HPV vaccination

Hybridisation step can be automated

Result interpretation with the AID GenoBlot Analyser

## STD assay

(RDB2110)

Designed for initial STD screening

Differentiation of the 5 most common pathogens causing STDs on one strip within 5 hours

Detection of *Chlamydia trachomatis* with deleted or mutated variant in the cryptic plasmid

CE<sub>0123</sub> third party certification

Conjugate control  
Amplification control  
HPV high risk  
HPV low risk  
HSV 1  
HSV 2  
*C. trachomatis*  
*N. gonorrhoeae*  
*T. pallidum*



## Literature

**Khan et al., 2005**

The Elevated 10-year Risk of Cervical Precancer and Cancer in Women with Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV-Testing in Clinical Practice  
*Journal of National Cancer Institute, Vol. 97, No.14, 2005*

**Hildesheim et al., 2007**

Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection  
*JAMA, Vol. 298, 743-753, 2007*

**Schneider et al., 2001**

Bedeutung des Nachweises von humanen Papillomaviren für die Vorsorge  
*Dt. Ärzteblatt 98: A2517-2521*